Citigroup’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.7M Buy
125,348
+72,543
+137% +$12.7M 0.01% 975
2025
Q4
$8.98M Sell
52,805
-134,301
-72% -$20.6M ﹤0.01% 1619
2025
Q3
$24.7M Buy
187,106
+10,114
+6% +$1.21M 0.01% 952
2025
Q2
$18.8M Buy
176,992
+3,998
+2% +$434K 0.01% 998
2025
Q1
$21.5M Buy
172,994
+135,309
+359% +$17.7M 0.01% 934
2024
Q4
$4.64M Sell
37,685
-5,118
-12% -$603K ﹤0.01% 2040
2024
Q3
$4.77M Buy
42,803
+20,767
+94% +$2.28M ﹤0.01% 1889
2024
Q2
$2.35M Sell
22,036
-44,098
-67% -$4.85M ﹤0.01% 2211
2024
Q1
$7.96M Sell
66,134
-2,925
-4% -$358K 0.01% 1395
2023
Q4
$8.49M Buy
69,059
+12,238
+22% +$1.53M 0.01% 1304
2023
Q3
$7.35M Sell
56,821
-5,826
-9% -$776K 0.01% 1253
2023
Q2
$7.77M Sell
62,647
-30,301
-33% -$4.08M 0.01% 1247
2023
Q1
$13.6M Sell
92,948
-3,928
-4% -$581K 0.01% 999
2022
Q4
$15.4M Sell
96,876
-12,750
-12% -$1.87M 0.01% 914
2022
Q3
$14.6M Buy
109,626
+66,272
+153% +$10.1M 0.01% 951
2022
Q2
$6.76M Sell
43,354
-2,513
-5% -$387K 0.01% 1351
2022
Q1
$7.14M Buy
45,867
+1,180
+3% +$171K ﹤0.01% 1477
2021
Q4
$5.69M Sell
44,687
-31,037
-41% -$4.08M ﹤0.01% 1731
2021
Q3
$9.86M Sell
75,724
-22,089
-23% -$3.34M 0.01% 1423
2021
Q2
$17.4M Sell
97,813
-52,028
-35% -$9.01M 0.01% 1077
2021
Q1
$24.6M Buy
149,841
+43,387
+41% +$7.14M 0.02% 840
2020
Q4
$17.6M Buy
106,454
+47,721
+81% +$7.11M 0.01% 1128
2020
Q3
$8.38M Sell
58,733
-22,985
-28% -$2.85M 0.01% 1511
2020
Q2
$9.02M Buy
81,718
+10,238
+14% +$1.13M 0.01% 1381
2020
Q1
$7.13M Sell
71,480
-1,121
-2% -$145K 0.01% 1396
2019
Q4
$10.8M Buy
72,601
+2,497
+4% +$340K 0.01% 1429
2019
Q3
$8.98M Sell
70,104
-16,199
-19% -$2.17M 0.01% 1474
2019
Q2
$12.3M Buy
86,303
+38,480
+80% +$5.17M 0.01% 1253
2019
Q1
$6.84M Sell
47,823
-48,104
-50% -$6.27M 0.01% 1546
2018
Q4
$11.9M Buy
95,927
+52,866
+123% +$7.84M 0.01% 1142
2018
Q3
$7.24M Buy
43,061
+3,203
+8% +$551K 0.01% 1522
2018
Q2
$6.87M Buy
39,858
+25,065
+169% +$4.1M 0.01% 1565
2018
Q1
$2.23M Sell
14,793
-2,609
-15% -$383K ﹤0.01% 2507
2017
Q4
$2.34M Sell
17,402
-23,432
-57% -$3.25M ﹤0.01% 2515
2017
Q3
$5.97M Buy
40,834
+23,646
+138% +$3.58M ﹤0.01% 1593
2017
Q2
$2.67M Buy
17,188
+2,436
+17% +$373K ﹤0.01% 2283
2017
Q1
$2.14M Buy
14,752
+10,443
+242% +$1.36M ﹤0.01% 2415
2016
Q4
$470K Sell
4,309
-14,993
-78% -$1.67M ﹤0.01% 4435
2016
Q3
$2.35M Buy
19,302
+7,811
+68% +$1.05M ﹤0.01% 2364
2016
Q2
$1.62M Sell
11,491
-4,134
-26% -$609K ﹤0.01% 2502
2016
Q1
$2.04M Buy
15,625
+1,582
+11% +$197K ﹤0.01% 2461
2015
Q4
$1.97M Buy
14,043
+8,434
+150% +$1.17M ﹤0.01% 2496
2015
Q3
$745K Sell
5,609
-17,307
-76% -$2.98M ﹤0.01% 3361
2015
Q2
$4.04M Sell
22,916
-15,756
-41% -$2.83M ﹤0.01% 1926
2015
Q1
$6.68M Buy
38,672
+12,641
+49% +$2.17M 0.01% 1500
2014
Q4
$4.26M Sell
26,031
-113,484
-81% -$18.8M ﹤0.01% 1909
2014
Q3
$22.4M Buy
139,515
+78,708
+129% +$12.1M 0.02% 731
2014
Q2
$8.94M Buy
60,807
+41,265
+211% +$5.72M 0.01% 1338
2014
Q1
$2.71M Sell
19,542
-682
-3% -$103K ﹤0.01% 2154
2013
Q4
$2.56M Buy
20,224
+6,801
+51% +$704K ﹤0.01% 2355
2013
Q3
$1.24M Buy
13,423
+11,455
+582% +$924K ﹤0.01% 2756
2013
Q2
$136K Buy
+1,968
New +$120K ﹤0.01% 4589

Other funds holding JAZZ

Citigroup's JAZZ Position: Q1 2026 in Review

Citigroup increased its Jazz Pharmaceuticals (JAZZ) stake by 137% in Q1 2026, buying an estimated $12.7M and bringing the position to 125,348 shares worth $23.7M. The position accounts for 0.01% of the portfolio, ranked #975.

Citigroup first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $24.7M in Q3 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Citigroup held 125,348 shares of Jazz Pharmaceuticals worth $23.7M as of Q1 2026.
  • Citigroup bought 72,543 Jazz Pharmaceuticals shares in Q1 2026, an estimated $12.7M.
  • Jazz Pharmaceuticals made up 0.01% of Citigroup's portfolio in Q1 2026, its #975 holding.
  • Citigroup first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Citigroup's Jazz Pharmaceuticals position peaked at $24.7M in Q3 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.